Get the Stockscreener App
5.26
0.22%
0.03
Aldeyra Therapeutics Inc stock is traded at $5.26, with a volume of 316.85K.
It is up +0.22% in the last 24 hours and up +0.03% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.23
Open:
$5.25
24h Volume:
316.85K
Relative Volume:
0.46
Market Cap:
$316.16M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-7.0133
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
+6.75%
1M Performance:
+0.03%
6M Performance:
+136.11%
1Y Performance:
+5.46%
1-Day Range:
$5.20
$5.345
1-Week Range:
$4.695
$5.345
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.255 | 314.65M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.29 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.77 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.27 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.92 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Why retail investors favor Aldeyra Therapeutics Inc. stock2025 Short Interest & Free Growth Oriented Trading Recommendations - newser.com
Aldeyra Therapeutics Inc Stock Analysis and ForecastContrarian Investment Ideas & Small Investment Trading Tips - earlytimes.in
What sentiment indicators say about Aldeyra Therapeutics Inc. stockJuly 2025 News Drivers & AI Based Buy/Sell Signal Reports - newser.com
Intraday pattern recognizer results for Aldeyra Therapeutics Inc.July 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
Aldeyra Therapeutics Inc. stock daily chart insightsTrend Reversal & AI Forecast Swing Trade Picks - newser.com
Understanding Aldeyra Therapeutics Inc.’s price movement - newser.com
Live market analysis of Aldeyra Therapeutics Inc.CEO Change & Short-Term High Return Ideas - newser.com
How Aldeyra Therapeutics Inc. stock performs in weak economyGap Down & Weekly Market Pulse Alerts - newser.com
Why Aldeyra Therapeutics Inc. stock is in analyst buy zonePortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Can a trend reversal in Aldeyra Therapeutics Inc. lead to recoveryPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Applying Wyckoff theory to Aldeyra Therapeutics Inc. stock2025 Market Trends & Daily Growth Stock Investment Tips - newser.com
What candlestick patterns are forming on Aldeyra Therapeutics Inc.Market Growth Report & Risk Managed Trade Strategies - newser.com
Aldeyra Therapeutics Inc.’s volatility index tracking explainedMarket Performance Recap & Real-Time Volume Surge Alerts - newser.com
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry EyeSlideshow (NASDAQ:ALDX) 2025-11-16 - Seeking Alpha
Sentiment analysis tools applied to Aldeyra Therapeutics Inc.July 2025 Recap & Weekly Market Pulse Alerts - newser.com
Smart tools for monitoring Aldeyra Therapeutics Inc.’s price actionWeekly Trading Summary & AI Forecast Swing Trade Picks - newser.com
What to expect from Aldeyra Therapeutics Inc. in the next 30 daysTrade Ideas & Weekly Top Gainers Trade List - newser.com
How Aldeyra Therapeutics Inc. stock responds to policy changes2025 Technical Patterns & Expert Approved Trade Ideas - Fundação Cultural do Pará
Is Aldeyra Therapeutics Inc. stock resilient to inflation2025 Market Sentiment & Accurate Intraday Trade Tips - Fundação Cultural do Pará
Is Aldeyra Therapeutics Inc. stock dividend yield sustainableQuarterly Market Summary & Pattern Based Trade Signal System - Fundação Cultural do Pará
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):